Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Kyntra Bio, Inc. (KYNB)
Company Research
Source: GlobeNewswire
Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and remains on track for interim analysis in 2H 2026Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC, further validating key Phase 2 monotherapy design elements, were presented at the 2026 ASCO GUSubmitted the pivotal Phase 3 clinical trial protocol for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden to the U.S. Food and Drug AdministrationCash, cash equivalents, investments, and accounts receivable of $109.4 million, providing cash runway into 2028Kyntra Bio to host conference call and webcast presentation today at 5:00 PM ET SAN FRANCISCO, March 16, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for t
Show less
Read more
Impact Snapshot
Event Time:
KYNB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYNB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYNB alerts
High impacting Kyntra Bio, Inc. news events
Weekly update
A roundup of the hottest topics
KYNB
News
- Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
- Kyntra Bio (KYNB) was upgraded by HC Wainwright to "strong-buy".MarketBeat
- Kyntra Bio to Participate in Upcoming Investor ConferencesGlobeNewswire
- Kyntra Bio (NASDAQ:KYNB) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Kyntra Bio (NASDAQ:KYNB) is now covered by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>. They set a "sell (d+)" rating on the stock.MarketBeat
KYNB
Earnings
- 3/16/26 - Beat
KYNB
Analyst Actions
- 2/28/26 - HC Wainwright